Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data
Conflicting data have been reported on the prognostic value of PD-L1 protein and gene expression in breast cancer. Medline, Embase, Cochrane Library, and Web of Science Core Collection were searched, and data were extracted independently by two researchers. Outcomes included pooled PD-L1 protein pos...
Saved in:
| Published in | Clinical cancer research Vol. 25; no. 18; pp. 5717 - 5726 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
15.09.2019
|
| Online Access | Get full text |
Cover
Loading…
| Abstract | Conflicting data have been reported on the prognostic value of PD-L1 protein and gene expression in breast cancer.
Medline, Embase, Cochrane Library, and Web of Science Core Collection were searched, and data were extracted independently by two researchers. Outcomes included pooled PD-L1 protein positivity in tumor cells, immune cells, or both, per subtype and per antibody used, and its prognostic value for disease-free and overall survival. A pooled gene expression analysis of 39 publicly available transcriptomic datasets was also performed.
Of the initial 4,184 entries, 38 retrospective studies fulfilled the predefined inclusion criteria. The overall pooled PD-L1 protein positivity rate was 24% (95% CI, 15%-33%) in tumor cells and 33% (95% CI, 14%- 56%) in immune cells. PD-L1 protein expression in tumor cells was prognostic for shorter overall survival (HR, 1.63; 95% CI, 1.07-2.46;
= 0.02); there was significant heterogeneity (
= 80%,
< 0.001). In addition, higher PD-L1 gene expression predicted better survival in multivariate analysis in the entire population (HR, 0.82; 95% CI, 0.74-0.90;
< 0.001 for OS) and in basal-like tumors (HR, 0.64; 95% CI, 0.52-0.80;
< 0.001 for OS;
0.005).
The largest to our knowledge meta-analysis on the subject informs on PD-L1 protein positivity rates and its prognostic value in breast cancer. Standardization is needed prior to routine implementation. PD-L1 gene expression is a promising prognostic factor, especially in basal-like breast cancer. Discrepant prognostic information might be related to PD-L1 gene expression in the stroma. |
|---|---|
| AbstractList | Conflicting data have been reported on the prognostic value of PD-L1 protein and gene expression in breast cancer.
Medline, Embase, Cochrane Library, and Web of Science Core Collection were searched, and data were extracted independently by two researchers. Outcomes included pooled PD-L1 protein positivity in tumor cells, immune cells, or both, per subtype and per antibody used, and its prognostic value for disease-free and overall survival. A pooled gene expression analysis of 39 publicly available transcriptomic datasets was also performed.
Of the initial 4,184 entries, 38 retrospective studies fulfilled the predefined inclusion criteria. The overall pooled PD-L1 protein positivity rate was 24% (95% CI, 15%-33%) in tumor cells and 33% (95% CI, 14%- 56%) in immune cells. PD-L1 protein expression in tumor cells was prognostic for shorter overall survival (HR, 1.63; 95% CI, 1.07-2.46;
= 0.02); there was significant heterogeneity (
= 80%,
< 0.001). In addition, higher PD-L1 gene expression predicted better survival in multivariate analysis in the entire population (HR, 0.82; 95% CI, 0.74-0.90;
< 0.001 for OS) and in basal-like tumors (HR, 0.64; 95% CI, 0.52-0.80;
< 0.001 for OS;
0.005).
The largest to our knowledge meta-analysis on the subject informs on PD-L1 protein positivity rates and its prognostic value in breast cancer. Standardization is needed prior to routine implementation. PD-L1 gene expression is a promising prognostic factor, especially in basal-like breast cancer. Discrepant prognostic information might be related to PD-L1 gene expression in the stroma. Conflicting data have been reported on the prognostic value of PD-L1 protein and gene expression in breast cancer.Experimental Design: Medline, Embase, Cochrane Library, and Web of Science Core Collection were searched, and data were extracted independently by two researchers. Outcomes included pooled PD-L1 protein positivity in tumor cells, immune cells, or both, per subtype and per antibody used, and its prognostic value for disease-free and overall survival. A pooled gene expression analysis of 39 publicly available transcriptomic datasets was also performed.PURPOSEConflicting data have been reported on the prognostic value of PD-L1 protein and gene expression in breast cancer.Experimental Design: Medline, Embase, Cochrane Library, and Web of Science Core Collection were searched, and data were extracted independently by two researchers. Outcomes included pooled PD-L1 protein positivity in tumor cells, immune cells, or both, per subtype and per antibody used, and its prognostic value for disease-free and overall survival. A pooled gene expression analysis of 39 publicly available transcriptomic datasets was also performed.Of the initial 4,184 entries, 38 retrospective studies fulfilled the predefined inclusion criteria. The overall pooled PD-L1 protein positivity rate was 24% (95% CI, 15%-33%) in tumor cells and 33% (95% CI, 14%- 56%) in immune cells. PD-L1 protein expression in tumor cells was prognostic for shorter overall survival (HR, 1.63; 95% CI, 1.07-2.46; P = 0.02); there was significant heterogeneity (I2 = 80%, P heterogeneity < 0.001). In addition, higher PD-L1 gene expression predicted better survival in multivariate analysis in the entire population (HR, 0.82; 95% CI, 0.74-0.90; P < 0.001 for OS) and in basal-like tumors (HR, 0.64; 95% CI, 0.52-0.80; P < 0.001 for OS; P interaction 0.005).RESULTSOf the initial 4,184 entries, 38 retrospective studies fulfilled the predefined inclusion criteria. The overall pooled PD-L1 protein positivity rate was 24% (95% CI, 15%-33%) in tumor cells and 33% (95% CI, 14%- 56%) in immune cells. PD-L1 protein expression in tumor cells was prognostic for shorter overall survival (HR, 1.63; 95% CI, 1.07-2.46; P = 0.02); there was significant heterogeneity (I2 = 80%, P heterogeneity < 0.001). In addition, higher PD-L1 gene expression predicted better survival in multivariate analysis in the entire population (HR, 0.82; 95% CI, 0.74-0.90; P < 0.001 for OS) and in basal-like tumors (HR, 0.64; 95% CI, 0.52-0.80; P < 0.001 for OS; P interaction 0.005).The largest to our knowledge meta-analysis on the subject informs on PD-L1 protein positivity rates and its prognostic value in breast cancer. Standardization is needed prior to routine implementation. PD-L1 gene expression is a promising prognostic factor, especially in basal-like breast cancer. Discrepant prognostic information might be related to PD-L1 gene expression in the stroma.CONCLUSIONSThe largest to our knowledge meta-analysis on the subject informs on PD-L1 protein positivity rates and its prognostic value in breast cancer. Standardization is needed prior to routine implementation. PD-L1 gene expression is a promising prognostic factor, especially in basal-like breast cancer. Discrepant prognostic information might be related to PD-L1 gene expression in the stroma. PURPOSE: Conflicting data have been reported on the prognostic value of PD-L1 protein and gene expression in breast cancer. EXPERIMENTAL DESIGN: Medline, Embase, Cochrane Library and Web of Science Core Collection were searched and data were extracted independently by two researchers. Outcomes included pooled PD-L1 protein positivity in tumor cells, immune cells or both, per subtype and per antibody used; and its prognostic value for disease-free and overall survival. A pooled gene expression analysis of 39 publicly available transcriptomic datasets was also performed. RESULTS: Of the initial 4184 entries, 38 retrospective studies fulfilled the predefined inclusion criteria. The overall pooled PD-L1 protein positivity rate was 24% (95% CI 15 - 33%) in tumor cells and 33% (95% CI 14 - 56%) in immune cells. PD-L1 protein expression in tumor cells was prognostic for shorter overall survival (HR = 1.63; 95% CI 1.07 - 2.46, p=0.02); there was significant heterogeneity (I2 = 80%, pheterogeneity<0.001). In addition, higher PD-L1 gene expression predicted better survival in multivariate analysis in the entire population (HR=0.82, 95% CI 0.74 - 0.90, p<0.001 for OS) and in basal-like tumors (HR=0.64, 95% CI 0.52 - 0.80, p<0.001 for OS), pinteraction 0.005. CONCLUSION: The largest to our knowledge meta-analysis on the subject informs on PD-L1 protein positivity rates and its prognostic value in breast cancer. Standardization is needed prior to routine implementation. PD-L1 gene expression is a promising prognostic factor, especially in basal-like BC. Discrepant prognostic information might be related to PD-L1 gene expression in the stroma. |
| Author | Matikas, Alexios Sotiriou, Christos Bergh, Jonas Foukakis, Theodoros Valachis, Antonios Richard, François Zerdes, Ioannis Lövrot, John |
| Author_xml | – sequence: 1 givenname: Alexios surname: Matikas fullname: Matikas, Alexios – sequence: 2 givenname: Ioannis surname: Zerdes fullname: Zerdes, Ioannis – sequence: 3 givenname: John orcidid: 0000-0002-9339-8059 surname: Lövrot fullname: Lövrot, John – sequence: 4 givenname: François orcidid: 0000-0003-4353-3619 surname: Richard fullname: Richard, François – sequence: 5 givenname: Christos surname: Sotiriou fullname: Sotiriou, Christos – sequence: 6 givenname: Jonas surname: Bergh fullname: Bergh, Jonas – sequence: 7 givenname: Antonios surname: Valachis fullname: Valachis, Antonios – sequence: 8 givenname: Theodoros orcidid: 0000-0001-8952-9987 surname: Foukakis fullname: Foukakis, Theodoros |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31227501$$D View this record in MEDLINE/PubMed https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-74782$$DView record from Swedish Publication Index http://kipublications.ki.se/Default.aspx?queryparsed=id:141936771$$DView record from Swedish Publication Index |
| BookMark | eNp9kttu1DAQhiNURA_wCCBfckGK7STrNVwtuy2stIhVKdxas86kNSR2ajuUfZ8-KN4TQkhwYY01-v7fh_lPsyPrLGbZc0bPGavGrxkV45yWBT-fTq9yJnPGCvYoO2FVJfKCj6qjtD8wx9lpCN8oZSWj5ZPsuGCci4qyk-xh6d2NdSEaTeZd3xoN0TgbiGvIcpYvGLn42XsMITWJseSdRwiRTMFq9G_I53WI2MFGfYU_DN4TsDX5iBFysNCug9k6zbtusO7WhOj0LXap-vWWXDrXYk0mf7DXHmzQ3vTRdcl2BhGeZo8baAM-29ez7MvlxfX0Q7749H4-nSxyXUoRc15hBXrUNKwqRc0bClIC5azhNSu5BoT0ZFGNShCNgNWK4YjKWqKUDHRdFMVZlu98wz32w0r13nTg18qBUfvW97RDVYqxpKPEv_onPzNfJ8r5m7QGJZKAJ_zlDu-9uxswRJV-QmPbgkU3BMV5mS5XSCES-mKPDqsO69_Oh8El4O0O0N6F4LFR2sTt6KIH0ypG1SYmahMBtYmASjFRTKpNTJK6-kt9OOD_ul8ke8Qs |
| CitedBy_id | crossref_primary_10_1002_ijc_33009 crossref_primary_10_1177_03009858241226621 crossref_primary_10_1007_s10549_024_07295_w crossref_primary_10_1136_jitc_2021_002500 crossref_primary_10_3389_fonc_2021_581030 crossref_primary_10_3390_diagnostics10090704 crossref_primary_10_1016_j_ejca_2020_05_014 crossref_primary_10_1186_s13058_020_01330_6 crossref_primary_10_3390_biom12020292 crossref_primary_10_1186_s12885_021_07970_x crossref_primary_10_1016_j_ctrv_2021_102257 crossref_primary_10_3390_cancers13205225 crossref_primary_10_1186_s13058_023_01717_1 crossref_primary_10_1158_1078_0432_CCR_22_1989 crossref_primary_10_1038_s41523_021_00352_3 crossref_primary_10_1002_ijc_35319 crossref_primary_10_1177_1758835920940928 crossref_primary_10_3390_ijms22020844 crossref_primary_10_3389_fbioe_2020_00141 crossref_primary_10_3389_fimmu_2023_1060308 crossref_primary_10_3390_cancers13184655 crossref_primary_10_3389_fimmu_2022_849468 crossref_primary_10_1016_j_bcp_2022_115209 crossref_primary_10_3390_ijms24076420 crossref_primary_10_4081_oncol_2021_533 crossref_primary_10_1177_03946320221078433 crossref_primary_10_2217_fon_2022_1321 crossref_primary_10_1111_bjh_18598 crossref_primary_10_3390_cancers12020361 crossref_primary_10_3390_data6070075 crossref_primary_10_1038_s41598_021_87216_9 crossref_primary_10_3390_nu16244415 crossref_primary_10_1007_s10549_021_06287_4 crossref_primary_10_1016_j_intimp_2023_111012 crossref_primary_10_1093_ejcts_ezaa172 crossref_primary_10_3390_cancers14041042 crossref_primary_10_1016_j_intimp_2021_107876 crossref_primary_10_3390_cancers13133371 crossref_primary_10_1016_j_ymthe_2020_12_034 crossref_primary_10_1038_s41523_025_00730_1 crossref_primary_10_1097_MD_0000000000034222 crossref_primary_10_1002_1878_0261_12654 crossref_primary_10_1038_s41598_023_33128_9 crossref_primary_10_1136_jcp_2024_209603 crossref_primary_10_3390_cancers13040746 crossref_primary_10_1016_j_vetimm_2020_110142 crossref_primary_10_1136_jitc_2024_010753 crossref_primary_10_1177_10781552221119797 crossref_primary_10_2147_BCTT_S333123 crossref_primary_10_1158_1078_0432_CCR_20_1731 crossref_primary_10_1186_s13058_023_01710_8 crossref_primary_10_1021_acs_molpharmaceut_3c01219 crossref_primary_10_1038_s41598_022_06830_3 crossref_primary_10_1007_s12282_020_01110_2 crossref_primary_10_1097_CEJ_0000000000000804 crossref_primary_10_1158_2159_8290_CD_22_0475 crossref_primary_10_3389_bjbs_2023_11065 crossref_primary_10_3390_cancers12020376 crossref_primary_10_1097_CM9_0000000000000710 crossref_primary_10_3389_fnagi_2023_1101216 crossref_primary_10_1016_j_annonc_2020_01_072 crossref_primary_10_1002_1878_0261_13435 crossref_primary_10_3390_cancers12092648 crossref_primary_10_1016_j_urolonc_2020_09_034 crossref_primary_10_1002_1878_0261_12747 crossref_primary_10_18502_sjms_v18i2_13602 |
| Cites_doi | 10.1056/NEJMoa1809615 10.1158/1078-0432.CCR-16-0979 10.1093/ajcp/aqx162 10.18632/oncotarget.18305 10.18632/oncotarget.15532 10.1080/15384047.2018.1423919 10.1038/nature12477 10.1158/1078-0432.CCR-17-1535 10.1093/jnci/djr545 10.1093/annonc/mdv478 10.1038/s41388-018-0303-3 10.1080/2162402X.2018.1509820 10.1186/s12967-016-0925-6 10.1186/s13058-017-0884-8 10.4048/jbc.2018.21.2.124 10.1038/s41598-017-11905-7 10.1056/NEJMc1713444 10.1016/S1470-2045(17)30904-X 10.1172/JCI96113 10.1136/jclinpath-2016-203990 10.1371/journal.pmed.1000100 10.4143/crt.2018.270 10.1007/s10549-016-4095-2 10.7150/jca.14549 10.1001/jamaoncol.2018.4224 10.1038/bjc.2017.446 10.1016/S0140-6736(14)62048-1 10.1186/bcr3148 10.1002/ijc.30552 10.4048/jbc.2016.19.3.242 10.1007/s10549-018-4745-7 10.1007/s10549-014-2988-5 10.1111/cas.13114 10.1158/1078-0432.CCR-07-4756 10.1371/journal.pone.0157368 10.7150/ijbs.20868 10.1186/s40064-016-2513-x 10.1007/s10549-018-4834-7 10.1007/s11523-016-0451-8 10.1186/s12885-017-3916-y 10.1093/ajcp/aqw134 10.1186/s12885-017-3670-1 10.1111/his.12904 10.2217/imt-2018-0116 10.1200/JCO.2008.18.1370 10.1158/2326-6066.CIR-13-0127 10.18632/oncotarget.14698 10.1158/1535-7163.MCT-17-1005 10.1016/j.breast.2017.06.013 10.1186/s12967-018-1458-y 10.21037/jtd.2017.12.52 10.18632/oncotarget.23717 10.18632/oncotarget.18316 10.1038/modpathol.2017.126 10.1186/s13058-018-1004-0 10.1371/journal.pmed.0050184 10.1186/s40425-018-0477-9 10.1016/j.humpath.2015.09.006 10.1371/journal.pmed.1001216 10.1097/COC.0000000000000426 10.1172/JCI96061 10.1371/journal.pone.0156323 10.1097/CAD.0000000000000683 10.18632/oncotarget.5583 10.1136/bmjebm-2018-110891 10.3390/ijms18020459 10.1136/esmoopen-2016-000150 10.1186/1745-6215-8-16 10.1002/j.1460-2075.1992.tb05481.x 10.1016/j.clbc.2015.07.006 10.1111/tbj.12753 |
| ContentType | Journal Article |
| Copyright | 2019 American Association for Cancer Research. |
| Copyright_xml | – notice: 2019 American Association for Cancer Research. |
| DBID | AAYXX CITATION NPM 7X8 ADTPV AOWAS D91 |
| DOI | 10.1158/1078-0432.CCR-19-1131 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic SwePub SwePub Articles SWEPUB Örebro universitet |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1557-3265 |
| EndPage | 5726 |
| ExternalDocumentID | oai_swepub_ki_se_478906 oai_DiVA_org_oru_74782 31227501 10_1158_1078_0432_CCR_19_1131 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- 18M 29B 2FS 2WC 34G 39C 53G 5GY 5RE 5VS 6J9 AAFWJ AAJMC AAYXX ABOCM ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW ADNWM AENEX AFHIN AFOSN AFRAH AFUMD ALMA_UNASSIGNED_HOLDINGS BAWUL BR6 BTFSW CITATION CS3 DIK DU5 E3Z EBS EJD F5P FRP GX1 H13 IH2 KQ8 L7B LSO OK1 P0W P2P QTD RCR RHI RNS SJN TR2 W2D W8F WOQ YKV NPM 7X8 .55 .GJ 1CY 3O- 4H- ADTPV AETEA AFFNX AI. AOWAS C1A D91 H~9 J5H MVM OHT UDS VH1 WHG X7M XJT ZCG ZGI |
| ID | FETCH-LOGICAL-c497t-25e5ac6ff1547d2f0a99a021f2d142caea5017564a7f7abb1e609d9e991acd333 |
| ISSN | 1078-0432 1557-3265 |
| IngestDate | Mon Aug 25 03:35:33 EDT 2025 Thu Aug 21 06:19:55 EDT 2025 Tue Aug 05 11:11:19 EDT 2025 Thu Apr 03 06:59:05 EDT 2025 Tue Jul 01 01:30:25 EDT 2025 Thu Apr 24 23:04:19 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 18 |
| Language | English |
| License | 2019 American Association for Cancer Research. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c497t-25e5ac6ff1547d2f0a99a021f2d142caea5017564a7f7abb1e609d9e991acd333 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0003-4353-3619 0000-0002-9339-8059 0000-0001-8952-9987 |
| OpenAccessLink | https://clincancerres.aacrjournals.org/content/clincanres/25/18/5717.full.pdf |
| PMID | 31227501 |
| PQID | 2245643977 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | swepub_primary_oai_swepub_ki_se_478906 swepub_primary_oai_DiVA_org_oru_74782 proquest_miscellaneous_2245643977 pubmed_primary_31227501 crossref_citationtrail_10_1158_1078_0432_CCR_19_1131 crossref_primary_10_1158_1078_0432_CCR_19_1131 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-09-15 |
| PublicationDateYYYYMMDD | 2019-09-15 |
| PublicationDate_xml | – month: 09 year: 2019 text: 2019-09-15 day: 15 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Clinical cancer research |
| PublicationTitleAlternate | Clin Cancer Res |
| PublicationYear | 2019 |
| References | Liberati (2022061101081588600_bib19) 2009; 6 Bae (2022061101081588600_bib30) 2016; 19 Li (2022061101081588600_bib12) 2016; 11 Muenst (2022061101081588600_bib48) 2014; 146 Ramasamy (2022061101081588600_bib71) 2008; 5 Mori (2022061101081588600_bib47) 2017; 8 Brockhoff (2022061101081588600_bib35) 2018; 9 Park (2022061101081588600_bib50) 2016; 16 Okabe (2022061101081588600_bib49) 2017; 108 Qin (2022061101081588600_bib54) 2015; 6 Botti (2022061101081588600_bib34) 2017; 18 Zhou (2022061101081588600_bib61) 2018; 29 He (2022061101081588600_bib39) 2018; 149 Lin (2022061101081588600_bib68) 2018; 128 Pelekanou (2022061101081588600_bib51) 2017; 19 Li (2022061101081588600_bib46) 2016; 7 Alexandrov (2022061101081588600_bib8) 2013; 500 Chen (2022061101081588600_bib36) 2017; 140 Acs (2022061101081588600_bib24) 2017; 35 Haibe-Kains (2022061101081588600_bib21) 2012; 104 Barrett (2022061101081588600_bib32) 2018; 20 Foukakis (2022061101081588600_bib66) 2018; 118 Tang (2022061101081588600_bib69) 2018; 128 Zhou (2022061101081588600_bib3) 2018; 6 Wang (2022061101081588600_bib60) 2018; 21 Lehmann (2022061101081588600_bib65) 2016; 11 Desmedt (2022061101081588600_bib64) 2008; 14 Denkert (2022061101081588600_bib67) 2018; 19 Guo (2022061101081588600_bib38) 2016; 5 Sun (2022061101081588600_bib57) 2016; 14 Choi (2022061101081588600_bib37) 2018; 41 Kim (2022061101081588600_bib40) 2017; 7 Guo (2022061101081588600_bib11) 2016; 11 Lundberg (2022061101081588600_bib22) 2017; 23 Beckers (2022061101081588600_bib33) 2016; 69 Pelekanou (2022061101081588600_bib52) 2018; 17 Zerdes (2022061101081588600_bib6) 2018; 37 Murad (2022061101081588600_bib70) 2018; 23 Asano (2022061101081588600_bib29) 2018; 16 Zhang (2022061101081588600_bib15) 2017; 8 Del Mastro (2022061101081588600_bib27) 2015; 385 Lee (2022061101081588600_bib42) 2019; 51 Emens (2022061101081588600_bib10) 2019; 5 Li (2022061101081588600_bib44) 2016; 146 Adams (2022061101081588600_bib25) 2018; 31 Arias-Pulido (2022061101081588600_bib28) 2018; 171 Altman (2022061101081588600_bib16) 2012; 9 Gourgou-Bourgade (2022061101081588600_bib17) 2015; 26 Wang (2022061101081588600_bib14) 2017; 23 Remon (2022061101081588600_bib5) 2018; 10 AiErken (2022061101081588600_bib26) 2017; 13 Mittendorf (2022061101081588600_bib62) 2014; 2 Bozovic-Spasojevic (2022061101081588600_bib20) 2017; 23 Kim (2022061101081588600_bib13) 2017; 17 Tierney (2022061101081588600_bib18) 2007; 8 Ishida (2022061101081588600_bib1) 1992; 11 Wang (2022061101081588600_bib59) 2017; 8 Schmid (2022061101081588600_bib9) 2018; 379 Parker (2022061101081588600_bib23) 2009; 27 Li (2022061101081588600_bib43) 2018; 18 Liu (2022061101081588600_bib63) 2012; 14 Li (2022061101081588600_bib2) 2018; 10 Kitano (2022061101081588600_bib41) 2017; 2 Yarchoan (2022061101081588600_bib7) 2017; 377 Li (2022061101081588600_bib45) 2018; 170 Tsang (2022061101081588600_bib58) 2017; 162 Baptista (2022061101081588600_bib31) 2016; 47 Wang (2022061101081588600_bib4) 2017; 8 Sobral-Leite (2022061101081588600_bib56) 2018; 7 Ren (2022061101081588600_bib55) 2018; 19 Polonia (2022061101081588600_bib53) 2017; 70 |
| References_xml | – volume: 379 start-page: 2108 year: 2018 ident: 2022061101081588600_bib9 article-title: Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1809615 – volume: 23 start-page: 2702 year: 2017 ident: 2022061101081588600_bib20 article-title: The prognostic role of androgen receptor in patients with early-stage breast cancer: a meta-analysis of clinical and gene expression data publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-16-0979 – volume: 149 start-page: 253 year: 2018 ident: 2022061101081588600_bib39 article-title: Expression of programmed death ligand 1 (PD-L1) in posttreatment primary inflammatory breast cancers and clinical implications publication-title: Am J Clin Pathol doi: 10.1093/ajcp/aqx162 – volume: 8 start-page: 51641 year: 2017 ident: 2022061101081588600_bib59 article-title: PD-L1 and intratumoral immune response in breast cancer publication-title: Oncotarget doi: 10.18632/oncotarget.18305 – volume: 8 start-page: 31347 year: 2017 ident: 2022061101081588600_bib15 article-title: Expression of PD-L1 and prognosis in breast cancer: a meta-analysis publication-title: Oncotarget doi: 10.18632/oncotarget.15532 – volume: 19 start-page: 373 year: 2018 ident: 2022061101081588600_bib55 article-title: PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer publication-title: Cancer Biol Ther doi: 10.1080/15384047.2018.1423919 – volume: 500 start-page: 415 year: 2013 ident: 2022061101081588600_bib8 article-title: Signatures of mutational processes in human cancer publication-title: Nature doi: 10.1038/nature12477 – volume: 23 start-page: 7512 year: 2017 ident: 2022061101081588600_bib22 article-title: Gene expression signatures and immunohistochemical subtypes add prognostic value to each other in breast cancer cohorts publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-1535 – volume: 104 start-page: 311 year: 2012 ident: 2022061101081588600_bib21 article-title: A three-gene model to robustly identify breast cancer molecular subtypes publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djr545 – volume: 26 start-page: 2505 year: 2015 ident: 2022061101081588600_bib17 article-title: Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) publication-title: Ann Oncol doi: 10.1093/annonc/mdv478 – volume: 37 start-page: 4639 year: 2018 ident: 2022061101081588600_bib6 article-title: Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations publication-title: Oncogene doi: 10.1038/s41388-018-0303-3 – volume: 7 start-page: e1509820 year: 2018 ident: 2022061101081588600_bib56 article-title: Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival publication-title: Oncoimmunology doi: 10.1080/2162402X.2018.1509820 – volume: 14 start-page: 173 year: 2016 ident: 2022061101081588600_bib57 article-title: Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies publication-title: J Transl Med doi: 10.1186/s12967-016-0925-6 – volume: 19 start-page: 91 year: 2017 ident: 2022061101081588600_bib51 article-title: Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance publication-title: Breast Cancer Res doi: 10.1186/s13058-017-0884-8 – volume: 21 start-page: 124 year: 2018 ident: 2022061101081588600_bib60 article-title: Lymphocyte-activation gene-3 expression and prognostic value in neoadjuvant-treated triple-negative breast cancer publication-title: J Breast Cancer doi: 10.4048/jbc.2018.21.2.124 – volume: 7 start-page: 11671 year: 2017 ident: 2022061101081588600_bib40 article-title: Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value publication-title: Sci Rep doi: 10.1038/s41598-017-11905-7 – volume: 377 start-page: 2500 year: 2017 ident: 2022061101081588600_bib7 article-title: Tumor mutational burden and response rate to PD-1 inhibition publication-title: N Engl J Med doi: 10.1056/NEJMc1713444 – volume: 19 start-page: 40 year: 2018 ident: 2022061101081588600_bib67 article-title: Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy publication-title: Lancet Oncol doi: 10.1016/S1470-2045(17)30904-X – volume: 128 start-page: 805 year: 2018 ident: 2022061101081588600_bib68 article-title: Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression publication-title: J Clin Invest doi: 10.1172/JCI96113 – volume: 70 start-page: 860 year: 2017 ident: 2022061101081588600_bib53 article-title: Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer publication-title: J Clin Pathol doi: 10.1136/jclinpath-2016-203990 – volume: 6 start-page: e1000100 year: 2009 ident: 2022061101081588600_bib19 article-title: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration publication-title: PLoS Med doi: 10.1371/journal.pmed.1000100 – volume: 51 start-page: 649 year: 2019 ident: 2022061101081588600_bib42 article-title: Prognostic role and clinical association of tumor-infiltrating lymphocyte, programmed death ligand-1 expression with neutrophil-lymphocyte ratio in locally advanced triple-negative breast cancer publication-title: Cancer Res Treat doi: 10.4143/crt.2018.270 – volume: 162 start-page: 19 year: 2017 ident: 2022061101081588600_bib58 article-title: PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-016-4095-2 – volume: 7 start-page: 784 year: 2016 ident: 2022061101081588600_bib46 article-title: PD-L1 expression is associated with tumor FOXP3(+) regulatory T-cell infiltration of breast cancer and poor prognosis of patient publication-title: J Cancer doi: 10.7150/jca.14549 – volume: 5 start-page: 74 year: 2019 ident: 2022061101081588600_bib10 article-title: Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2018.4224 – volume: 118 start-page: 480 year: 2018 ident: 2022061101081588600_bib66 article-title: Immune gene expression and response to chemotherapy in advanced breast cancer publication-title: Br J Cancer doi: 10.1038/bjc.2017.446 – volume: 385 start-page: 1863 year: 2015 ident: 2022061101081588600_bib27 article-title: Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 x 2 factorial, randomised phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(14)62048-1 – volume: 14 start-page: R48 year: 2012 ident: 2022061101081588600_bib63 article-title: CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer publication-title: Breast Cancer Res doi: 10.1186/bcr3148 – volume: 140 start-page: 1384 year: 2017 ident: 2022061101081588600_bib36 article-title: PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy publication-title: Int J Cancer doi: 10.1002/ijc.30552 – volume: 19 start-page: 242 year: 2016 ident: 2022061101081588600_bib30 article-title: Expression of programmed death receptor ligand 1 with high tumor-infiltrating lymphocytes is associated with better prognosis in breast cancer publication-title: J Breast Cancer doi: 10.4048/jbc.2016.19.3.242 – volume: 170 start-page: 293 year: 2018 ident: 2022061101081588600_bib45 article-title: The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-018-4745-7 – volume: 146 start-page: 15 year: 2014 ident: 2022061101081588600_bib48 article-title: Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-014-2988-5 – volume: 108 start-page: 81 year: 2017 ident: 2022061101081588600_bib49 article-title: Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer publication-title: Cancer Sci doi: 10.1111/cas.13114 – volume: 14 start-page: 5158 year: 2008 ident: 2022061101081588600_bib64 article-title: Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-4756 – volume: 11 start-page: e0157368 year: 2016 ident: 2022061101081588600_bib65 article-title: Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection publication-title: PLoS One doi: 10.1371/journal.pone.0157368 – volume: 13 start-page: 1172 year: 2017 ident: 2022061101081588600_bib26 article-title: High PD-L1 expression is closely associated with tumor-infiltrating lymphocytes and leads to good clinical outcomes in Chinese triple negative breast cancer patients publication-title: Int J Biol Sci doi: 10.7150/ijbs.20868 – volume: 5 start-page: 805 year: 2016 ident: 2022061101081588600_bib38 article-title: PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker publication-title: Springerplus doi: 10.1186/s40064-016-2513-x – volume: 171 start-page: 273 year: 2018 ident: 2022061101081588600_bib28 article-title: The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-018-4834-7 – volume: 11 start-page: 753 year: 2016 ident: 2022061101081588600_bib12 article-title: Prognostic role of programmed death ligand-1 expression in breast cancer: a systematic review and meta-analysis publication-title: Target Oncol doi: 10.1007/s11523-016-0451-8 – volume: 18 start-page: 4 year: 2018 ident: 2022061101081588600_bib43 article-title: Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer publication-title: BMC Cancer doi: 10.1186/s12885-017-3916-y – volume: 146 start-page: 496 year: 2016 ident: 2022061101081588600_bib44 article-title: Stromal PD-L1 expression is associated with better disease-free survival in triple-negative breast cancer publication-title: Am J Clin Pathol doi: 10.1093/ajcp/aqw134 – volume: 17 start-page: 690 year: 2017 ident: 2022061101081588600_bib13 article-title: Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis publication-title: BMC Cancer doi: 10.1186/s12885-017-3670-1 – volume: 69 start-page: 25 year: 2016 ident: 2022061101081588600_bib33 article-title: Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome publication-title: Histopathology doi: 10.1111/his.12904 – volume: 10 start-page: 1293 year: 2018 ident: 2022061101081588600_bib2 article-title: Efficacy and safety of PD-1 inhibitors for treating advanced melanoma: a systematic review and meta-analysis publication-title: Immunotherapy doi: 10.2217/imt-2018-0116 – volume: 27 start-page: 1160 year: 2009 ident: 2022061101081588600_bib23 article-title: Supervised risk predictor of breast cancer based on intrinsic subtypes publication-title: J Clin Oncol doi: 10.1200/JCO.2008.18.1370 – volume: 2 start-page: 361 year: 2014 ident: 2022061101081588600_bib62 article-title: PD-L1 expression in triple-negative breast cancer publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-13-0127 – volume: 8 start-page: 15584 year: 2017 ident: 2022061101081588600_bib47 article-title: The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer publication-title: Oncotarget doi: 10.18632/oncotarget.14698 – volume: 17 start-page: 1324 year: 2018 ident: 2022061101081588600_bib52 article-title: Tumor-infiltrating lymphocytes and PD-L1 expression in pre- and posttreatment breast cancers in the SWOG S0800 phase II neoadjuvant chemotherapy trial publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-17-1005 – volume: 35 start-page: 69 year: 2017 ident: 2022061101081588600_bib24 article-title: PD-1, PD-L1 and CTLA-4 in pregnancy-related - and in early-onset breast cancer: A comparative study publication-title: Breast doi: 10.1016/j.breast.2017.06.013 – volume: 16 start-page: 87 year: 2018 ident: 2022061101081588600_bib29 article-title: Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression publication-title: J Transl Med doi: 10.1186/s12967-018-1458-y – volume: 10 start-page: S1516 year: 2018 ident: 2022061101081588600_bib5 article-title: Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients publication-title: J Thorac Dis doi: 10.21037/jtd.2017.12.52 – volume: 9 start-page: 6201 year: 2018 ident: 2022061101081588600_bib35 article-title: The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease publication-title: Oncotarget doi: 10.18632/oncotarget.23717 – volume: 8 start-page: 59901 year: 2017 ident: 2022061101081588600_bib4 article-title: Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis publication-title: Oncotarget doi: 10.18632/oncotarget.18316 – volume: 31 start-page: 288 year: 2018 ident: 2022061101081588600_bib25 article-title: Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer publication-title: Mod Pathol doi: 10.1038/modpathol.2017.126 – volume: 20 start-page: 71 year: 2018 ident: 2022061101081588600_bib32 article-title: The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers publication-title: Breast Cancer Res doi: 10.1186/s13058-018-1004-0 – volume: 5 start-page: e184 year: 2008 ident: 2022061101081588600_bib71 article-title: Key issues in conducting a meta-analysis of gene expression microarray datasets publication-title: PLoS Med doi: 10.1371/journal.pmed.0050184 – volume: 6 start-page: 155 year: 2018 ident: 2022061101081588600_bib3 article-title: Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis publication-title: J Immunother Cancer doi: 10.1186/s40425-018-0477-9 – volume: 47 start-page: 78 year: 2016 ident: 2022061101081588600_bib31 article-title: Prognostic significance of PD-L1 and PD-L2 in breast cancer publication-title: Hum Pathol doi: 10.1016/j.humpath.2015.09.006 – volume: 9 start-page: e1001216 year: 2012 ident: 2022061101081588600_bib16 article-title: Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration publication-title: PLoS Med doi: 10.1371/journal.pmed.1001216 – volume: 41 start-page: 1049 year: 2018 ident: 2022061101081588600_bib37 article-title: Differential prognostic impact of strong PD-L1 expression and 18F-FDG uptake in triple-negative breast cancer publication-title: Am J Clin Oncol doi: 10.1097/COC.0000000000000426 – volume: 128 start-page: 580 year: 2018 ident: 2022061101081588600_bib69 article-title: PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression publication-title: J Clin Invest doi: 10.1172/JCI96061 – volume: 11 start-page: e0156323 year: 2016 ident: 2022061101081588600_bib11 article-title: Prognostic and clinicopathological value of programmed death ligand-1 in breast cancer: a meta-analysis publication-title: PLoS One doi: 10.1371/journal.pone.0156323 – volume: 29 start-page: 904 year: 2018 ident: 2022061101081588600_bib61 article-title: Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis publication-title: Anticancer Drugs doi: 10.1097/CAD.0000000000000683 – volume: 6 start-page: 33972 year: 2015 ident: 2022061101081588600_bib54 article-title: High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer publication-title: Oncotarget doi: 10.18632/oncotarget.5583 – volume: 23 start-page: 84 year: 2018 ident: 2022061101081588600_bib70 article-title: The effect of publication bias magnitude and direction on the certainty in evidence publication-title: BMJ Evid Based Med doi: 10.1136/bmjebm-2018-110891 – volume: 18 year: 2017 ident: 2022061101081588600_bib34 article-title: Programmed Death Ligand 1 (PD-L1) tumor expression is associated with a better prognosis and diabetic disease in triple negative breast cancer patients publication-title: Int J Mol Sci doi: 10.3390/ijms18020459 – volume: 2 start-page: e000150 year: 2017 ident: 2022061101081588600_bib41 article-title: Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer publication-title: ESMO Open doi: 10.1136/esmoopen-2016-000150 – volume: 8 start-page: 16 year: 2007 ident: 2022061101081588600_bib18 article-title: Practical methods for incorporating summary time-to-event data into meta-analysis publication-title: Trials doi: 10.1186/1745-6215-8-16 – volume: 11 start-page: 3887 year: 1992 ident: 2022061101081588600_bib1 article-title: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death publication-title: EMBO J doi: 10.1002/j.1460-2075.1992.tb05481.x – volume: 16 start-page: 51 year: 2016 ident: 2022061101081588600_bib50 article-title: Prognostic implications of tumor-infiltrating lymphocytes in association with programmed death ligand 1 expression in early-stage breast cancer publication-title: Clin Breast Cancer doi: 10.1016/j.clbc.2015.07.006 – volume: 23 start-page: 436 year: 2017 ident: 2022061101081588600_bib14 article-title: Prognostic value of PD-L1 in breast cancer: a meta-analysis publication-title: Breast J doi: 10.1111/tbj.12753 |
| SSID | ssj0014104 |
| Score | 2.561269 |
| Snippet | Conflicting data have been reported on the prognostic value of PD-L1 protein and gene expression in breast cancer.
Medline, Embase, Cochrane Library, and Web... Conflicting data have been reported on the prognostic value of PD-L1 protein and gene expression in breast cancer.Experimental Design: Medline, Embase,... PURPOSE: Conflicting data have been reported on the prognostic value of PD-L1 protein and gene expression in breast cancer. EXPERIMENTAL DESIGN: Medline,... |
| SourceID | swepub proquest pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 5717 |
| Title | Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31227501 https://www.proquest.com/docview/2245643977 https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-74782 http://kipublications.ki.se/Default.aspx?queryparsed=id:141936771 |
| Volume | 25 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3di9QwEA9ygvgifrueSgX1Rbpu0iRtwZdzTzn1VkTu5PAlpE0q5aQ9atcH_3pnkrS7d7vg6cOWkrTJMjOdzCTzmyHkWQo2gp0ZEZepYTEXVRYXKRpysqxoAiIlHI578UkeHPMPJ-JkVYzToUv6Ylr-3oor-R-uQhvwFVGy_8DZcVBogHvgL1yBw3C9FI8_dy3GyWHO1Xo9Mhzj2vbjQ4r5-32cq4tnLDAAvcc4rzLE5A4pCgZ4pO96GTIAjTvFCxj31CO_EBBTt6Mh_s12JiiaFqsfjR2HeAL_Rv7q2v5ixG_A8g9mszuqT9v63AYEdRFWHoI56EwBeor5kg-DUmViXXiyNRUpUg_W3NTdInPbCJjylydsOp9_iWE2SsMysZkWe7_-uqfa7jv8lgoLAcBafJWBv-B86_cfx-MkTl0dyXFsl0Q3_OsA64LZX22d-7zBsuGFXEgx68ySo5vkRvAnoj0vHLfIFdvcJtcWIWLiDnm9kpFoXUaitoqcjEQrGYnqJvIyEnlBuEuO3709mh_EoWJGXPI87WMmrNClrCowjOHbq2Y6zzVYcRUzlLNSWy1AAwvJdVqluiiolbPc5BacBF2aJEnukZ2mbewDEsFSaTSHB40EQ0dm4KdnVcETIwtjE20mhA9kUWVIJ49VTX4o51aKTCE1FVJTATUVzRVSc0Km42tnPp_K3154OtBcgebD4yzd2Hb5UzE8s0d7Op2Q-54Z45AJZVi4AN5-7rkz9myXmwl5seW50HQKd1ZxhIzLh5cccJdcX30rj8hO3y3tYzBf--KJE80_KHyUxQ |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+implications+of+PD-L1+expression+in+breast+cancer&rft.jtitle=Clinical+cancer+research&rft.au=Matikas%2C+Alexios&rft.au=Zerdes%2C+Ioannis&rft.au=L%C3%B6vrot%2C+John&rft.au=Richard%2C+Fran%C3%A7ois&rft.date=2019-09-15&rft.issn=1557-3265&rft.volume=25&rft.issue=18&rft.spage=5717&rft_id=info:doi/10.1158%2F1078-0432.CCR-19-1131&rft.externalDocID=oai_DiVA_org_oru_74782 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon |